Tapentadol is the strong pain medicine that contains an opioid that is used to manage pain severe enough to require daily around-the-clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your pain well enough or you cannot tolerate them.
Tapentadol also used to manage pain from damaged nerves (neuropathic pain) that happens with diabetes and is severe enough to require daily around-the-clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.
A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse. Tapentadol not used to treat pain that is not around-the-clock pain. Tapentadol brand names: Nucynta, Palexia, Yantil, Tapenta, Tapal. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu‑opioid receptor agonist and a norepinephrine reuptake inhibitor.
What kind of pain Tapentadol treat
Two main types of pathophysiology are often the cause for pain in the majority of patients, nociceptive pain and neuropathic pain. Common ypes of chronic pain, including diabetic peripheral neuropathy and conditions that originate or are common to the low back. Patients with chronic pain conditions may have both a neuropathic and a nociceptive component.
Diabetic peripheral neuropathy. A complication of diabetes in which high blood glucose may damage the tiny blood vessels carrying oxygen and nutrients to the small nerves in the hands and feet.
Intervertebral disc disease. A condition typically caused by aging in which discs in the vertebral column deteriorate or herniate, causing them to lose fluid, elasticity, and shock-absorbing capabilities.
Radiculopathy. Nerve damage typically caused by inflammation or impingement of a nerve root, causing weakness or pain radiating the length of the nerve.
Arthritis. There are several forms of arthritis of the spine (known altogether as spondyloarthropathies).
Osteoarthritis. Occurs when the cartilage that protects the bones of the spinal area breaks down, causing bones to rub together, which leads to spurs that press against nerves.
Rheumatoid Arthritis. Occurs when the immune system attacks soft tissue surrounding the joints of the spine, which can place pressure on the spinal cord or spinal nerve roots.
Ankylosing Spondylitis. An inflammatory disease in which the ligaments and bones of the spine fuse together, resulting in a stiff, fused, painful spine.
Spondylolisthesis. A condition in which a lower vertebra slides out of place on top of the vertebra below it, commonly between L4 and L5, causing low back pain.
Despite the availability of new therapies, neuropathic pain continues to pose challenges to patients and practitioners alike. It is often chronic in nature and, in a substantial number of patients, is relieved only by medication such as Tapentadol. The mainstay of treatment for most types of neuropathic pain consists of antidepressants, anticonvulsants, topical anesthetics, and opioid analgesics. Only a handful, however, have been FDA approved. In order to achieve clinically meaningful pain relief, patients commonly require Tapentadol. Treatment is often complicated by coexisting health conditions, and current guidelines recommend a highly individualized approach to management. Practitioners can play a key role in helping patients optimize drug therapy and minimize the consequences.
In USA chronic pain is a challenging, widespread problem. Pain management and primary care physicians are often faced with nonmalignant pain syndromes and with those suffering from neuropathic pain. While potent opioids are associated with significant adverse events, nonopioid analgesics may not be sufficient to achieve adequate analgesia among patients with moderate to severe chronic pain.
Individualize therapy taking into consideration severity of pain, response to therapy, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse. For the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Extended Release Nucynta Tablets, as the name would suggest, lasts longer than the immediate release counterpart.
Usual Adult Dose for Pain:
Tapentadol comes as a tablet and an extended-release (long acting) tablet to take by mouth. The tablets are usually taken with or without food as needed. Initial dose: 50 mg to 100 mg orally every 4 to 6 hours as needed for pain. A second dose may be administered as soon as 1 hour after the first dose if needed. Subsequent dosing: 50 mg, 75 mg, or 100 mg orally every 4 to 6 hours. Adjust dosing to maintain adequate analgesia with acceptable tolerability. Maximum daily dose: 700 mg.